ArticleiScience2026
Effects of Pep19 on adipose tissue distribution and metabolic parameters in adults with obesity: A randomized, double-blind, placebo-controlled trial.
Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Whether modulation of adipose tissue distribution alone can improve insulin sensitivity independently of weight loss remains unclear. In this randomized, double-blind, placebo-controlled 90-day trial, we investigated whether adults with obesity could achieve metabolic improvement through modulation of adipose tissue distribution independent of weight loss. Fifty-six participants received oral placebo or Pep19 (5 or 10 mg daily). Regional fat distribution and metabolic parameters were assessed longitudinally. Pep19 at 10 mg reduced central adiposity, as demonstrated by a reduced android-to-gynoid fat ratio and decreased abdominal skinfold thickness, without affecting body weight, caloric intake, or physical activity. Glycated hemoglobin (HbA1c) and HOMA-IR were significantly reduced, despite unchanged fasting glucose, indicating improved insulin sensitivity. These findings suggest that Pep19 promotes favorable changes in adipose tissue distribution accompanied by improvements in insulin sensitivity independent of significant weight loss, supporting further evaluation in larger and longer-term clinical studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.